Page last updated: 2024-09-03

vadimezan and Carcinoma, Non-Small Cell Lung

vadimezan has been researched along with Carcinoma, Non-Small Cell Lung in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (50.00)	29.6817
2010's	6 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aghaei, M; Downey, CM; Jirik, FR; Schwendener, RA	1
He, ZX; Pan, ST; Qiu, JX; Wang, D; Yang, T; Yang, YX; Zhang, X; Zhou, SF; Zhou, ZW	1
Döme, B; Magyar, M	1
Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J	1
Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J	1
Castaldo, V; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Sacco, PC	1
Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N	1
McKeage, MJ	1
Boerner, SA; Hunsberger, S; Lorusso, PM	1
Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J	1
Raben, D; Ryan, A	1

Reviews

4 review(s) available for vadimezan and Carcinoma, Non-Small Cell Lung

Article	Year
[Tumor vasculature as a therapeutic target in non-small cell lung cancer]. Magyar onkologia, 2008, Volume: 52, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones	2008
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. The oncologist, 2009, Volume: 14, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diketopiperazines; Endothelial Cells; Humans; Imidazoles; Lung Neoplasms; Pericytes; Piperazines; Stilbenes; Sulfonamides; Xanthones	2009
Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer. Clinical lung cancer, 2011, Volume: 12, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Xanthones	2011
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Vascular Endothelial Growth Factors; Xanthones	2005

Trials

4 trial(s) available for vadimezan and Carcinoma, Non-Small Cell Lung

Article	Year
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British journal of cancer, 2008, Dec-16, Volume: 99, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones	2008
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones	2009
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer science, 2011, Volume: 102, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones	2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones	2011

Other Studies

4 other study(ies) available for vadimezan and Carcinoma, Non-Small Cell Lung

Article	Year
DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PloS one, 2014, Volume: 9, Issue:6 Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Cell Polarity; Clodronic Acid; Humans; Inflammation; Liposomes; Lung Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Transgenic; Necrosis; Neovascularization, Pathologic; Nucleotides, Cyclic; Phenotype; ras Proteins; Subcutaneous Tissue; Tumor Suppressor Protein p53; Xanthones; Xenograft Model Antitumor Assays	2014
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug design, development and therapy, 2015, Volume: 9 Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Humans; Isotope Labeling; Lung Neoplasms; Neoplasm Proteins; Proteome; Proteomics; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Xanthones	2015
Molecule of the month. Vadimezan. Drug news & perspectives, 2009, Volume: 22, Issue:9 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Treatment Outcome; Xanthones	2009
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Drug Synergism; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Failure; Vascular Endothelial Growth Factor A; Xanthones	2011